Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant versus exemestane after prior non-steroidal aromatase inhibitor therapy in advanced hormone receptor-positive breast cancer
2004-000727-15Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Faslodex with Aromasin (2 arms). Primary endpoint: Time to disease progression. Started Sep 2004; status: completed.
02
Drugs
fulvestrantexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2004-000727-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000727-15.